

**In Pursuit of Stability Enhancement of a Prostate Cancer Targeting Antibody
Derived from a Transgenic Animal Platform**

*Sathya Venkataramani¹, Robin Ernst¹, Mehabaw Derebe¹, Robert Wright¹, Jessica Kopenhaver¹,
Steven Jacobs¹, Sanjaya Singh¹ and Rajkumar Ganesan^{1*}*

¹Janssen Biotherapeutics, 1400 McKean Road, Spring House, PA 19477

*Correspondence

Rajkumar Ganesan
Janssen Biotherapeutics
1400 McKean Road,
Spring House, PA 19477
Ph: (215) 628-6880
Email: rganesa3@its.inj.com

Supplementary information

Figure S1: (a) Sequence alignment of an anti-PSMA heavy chain (VH) with human germline IGHV4-39*01 and its engineered variant. An unusual framework residue (Ile) at position 68 was re-engineered to Thr. (b) Relative positional frequency of the SHM using the abYsis portal. (c) Intrinsic properties characterization of anti-PSMA using Differential Scanning Fluorimetry (DSF). An improvement in both T_m and T_{agg} was observed for the engineered variant.


Figure S2: (a) Sequence alignment of an anti-DLL3 heavy chain (VH) with human germline IGHV3-13*05 and the light chain (Vk) with human germline IGKV1-5*03 and a series of engineered variants. Two unusual framework residues at position 85 (in the VH) and at position 84 (in VL) were re-engineered. (b) The composition of mutations in VH and Vk for the three engineered variants (c) Intrinsic properties characterization of an anti-DLL3 using Differential Scanning Fluorimetry (DSF). An improvement in both T_m and T_{agg} was observed for the engineered variant. (d) Relative positional frequency of His85 (in VH) using the abYsis portal. (e) Relative positional frequency of Glu84 (in Vk) using the abYsis portal.

Supplementary Figure – S1


A

Heavy chain
 Framework-1
 Anti-PSMA_wildtype RVI^{I68T}MSVDTSKNQFSLKLSVTAADTALYYCAS
 IGHV4-39*01 RVTISVDTSKNQFSLKLSVTAADTAVYYCAR
 Anti-PSMA_variant1 RVTISVDTSKNQFSLKLSVTAADTALYYCAS

B



C



Supplementary Figure – S2

A

Heavy chain_Framework-3

ANTI-DLL3_HC	RFTISRENVKHSLYLQMNSLRVGD T AVYFCAR
IGHV3-13*05	RFTISRENAKNSLYLQMNSLRAGDTAVYYCAR
ANTI-DLL3_variant-1_HC	RFTISRENVKNSLYLQMNSLRVGD T AVYFCAR
ANTI-DLL3_variant-2_HC	RFTISRENVKNSLYLQMNSLRVGD T AVYFCAR
ANTI-DLL3_variant-3_HC	RFTISRENVKHSLYLQMNSLRVGD T AVYFCAR


Light chain_Framework-3

ANTI-DLL3_LC	GVPSRFSGSGSSETEFTLTISLQPD D FATYYC
IGKV1-5*03	GVPSRFSGSGSGTEFTLTISLQPD D FATYYC
ANTI-DLL3_variant-1-LC	GVPSRFSGSGSSETEFTLTISLQPD D FATYYC
ANTI-DLL3_variant-2-LC	GVPSRFSGSGSGTEFTLTISLQPD D FATYYC
ANTI-DLL3_variant-3-LC	GVPSRFSGSGSGTEFTLTISLQPD D FATYYC


B

#	Name	Heavy chain	Light chain
1	Anti-DLL3-wildtype	DLL3_HC	DLL3_LC
2	Anti-DLL3-variant1 (V1)	DLL3_HC_H85N	DLL3_LC
3	Anti-DLL3-variant2 (V2)	DLL3_HC_H85N	DLL3_LC_E84G
4	Anti-DLL3-variant3 (V3)	DLL3_HC	DLL3_LC_E84G

C



D



E

